Follicular lymphoma trials in Taiwan

In Taiwan 8 Also abroad 188

8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Where
Taipei, Taoyuan
Age
18 years and over
People
960 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00
Phase 3Taking people
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Where
Changhua, Kaohsiung City, Lukang Township, Tainan, Taipei
Age
18 years to 130 years
People
1,018 worldwide
Run by
AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01
Phase 2Taking people
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Where
Kaohsiung City, Taichung, Tainan, Taipei
Age
18 years and over
People
270 worldwide
Run by
AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00
No phaseTaking people
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Where
Kaohsiung, Tainan, Taipei
People
49
Run by
Pell Bio-Med Technology Co., Ltd.
See details and how to joinNCT05377307
Phase 3Taking people
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Where
Buzi, Changhua, Kaohsiung City, New Taipei City, Tainan, Taipei, Taoyuan City
Age
18 years and over
People
580 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06149286 · EU 2022-503092-28-00
Phase 3Taking people
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Where
Buzi, Changhua, Kaohsiung City, New Taipei City, Taichung, Tainan, Taipei, Taoyuan City
Age
18 years and over
People
822 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091254 · EU 2022-502660-20-00
Phase 1Taking people
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Where
Taipei
Age
18 years to 70 years
People
18
Run by
GenomeFrontier Therapeutics TW Co., Ltd.
See details and how to joinNCT06703892
No phaseEnrolling by invitation
Long-term Study to Evaluate Safety and Persistence of GF-CART01
Where
Taipei
People
18
Run by
GenomeFrontier Therapeutics TW Co., Ltd.
See details and how to joinNCT06985576